ATE530544T1 - Benzyl-substituierte positive allosterische chinolon-m1-rezeptormodulatoren - Google Patents

Benzyl-substituierte positive allosterische chinolon-m1-rezeptormodulatoren

Info

Publication number
ATE530544T1
ATE530544T1 AT07796508T AT07796508T ATE530544T1 AT E530544 T1 ATE530544 T1 AT E530544T1 AT 07796508 T AT07796508 T AT 07796508T AT 07796508 T AT07796508 T AT 07796508T AT E530544 T1 ATE530544 T1 AT E530544T1
Authority
AT
Austria
Prior art keywords
benzyl
positive allosteric
quinolone
receptor modulators
receptor
Prior art date
Application number
AT07796508T
Other languages
English (en)
Inventor
Craig Lindsley
William D Shipe
Feng Yang
Jaime Bunda
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Application granted granted Critical
Publication of ATE530544T1 publication Critical patent/ATE530544T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT07796508T 2006-06-28 2007-06-27 Benzyl-substituierte positive allosterische chinolon-m1-rezeptormodulatoren ATE530544T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81711306P 2006-06-28 2006-06-28
PCT/US2007/014943 WO2008002621A2 (en) 2006-06-28 2007-06-27 Benzyl-substituted quinolone m1 receptor positive allosteric modulators

Publications (1)

Publication Number Publication Date
ATE530544T1 true ATE530544T1 (de) 2011-11-15

Family

ID=38846301

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07796508T ATE530544T1 (de) 2006-06-28 2007-06-27 Benzyl-substituierte positive allosterische chinolon-m1-rezeptormodulatoren

Country Status (7)

Country Link
US (1) US8178667B2 (de)
EP (1) EP2037739B1 (de)
JP (1) JP2009542663A (de)
AT (1) ATE530544T1 (de)
AU (1) AU2007265412A1 (de)
CA (1) CA2655787A1 (de)
WO (1) WO2008002621A2 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011512357A (ja) * 2008-02-15 2011-04-21 メルク・シャープ・エンド・ドーム・コーポレイション 縮合ピリドンm1受容体ポジティブアロステリックモジュレーター
WO2009151683A2 (en) 2008-03-12 2009-12-17 Link Medicine Corporation Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
US8293914B2 (en) 2008-05-01 2012-10-23 Merck Sharp & Dohme Corp. 4-OXO,1-4-dihydroquinoline M1 receptor positive allosteric modulators
EP2312949B1 (de) * 2008-08-12 2013-08-28 Merck Sharp & Dohme Corp. Positive allosterische n-heterozyklische m1-rezeptormodulatoren
AU2009313927A1 (en) 2008-11-13 2010-05-20 Astrazeneca Ab Azaquinolinone derivatives and uses thereof
US8557832B2 (en) * 2008-11-20 2013-10-15 Merck Sharp & Dohme Corp. Aryl methyl benzoquinazolinine M1 receptor positive allosteric modulators
JP2012518640A (ja) * 2009-02-23 2012-08-16 メルク・シャープ・エンド・ドーム・コーポレイション ピラゾロ[4,3−c]シンノリン−3−オンM1受容体陽性アロステリックモジュレーター
CN102480964B (zh) * 2009-08-31 2015-07-08 默沙东公司 吡喃基芳基甲基苯并喹唑啉酮m1受体正向别构调节剂
WO2011041143A1 (en) * 2009-10-01 2011-04-07 Merck Sharp & Dohme Corp. HETEROCYCLIC-FUSED PYRAZOLO[4,3-c]PYRIDIN-3-ONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS
US8895580B2 (en) 2009-10-21 2014-11-25 Merck Sharp & Dohme Corp. Quinolinone-pyrazolone M1 receptor positive allosteric modulators
WO2011075371A1 (en) * 2009-12-14 2011-06-23 Merck Sharp & Dohme Corp. Pyridoquinazolinone m1 receptor positive allosteric modulators
WO2011084371A1 (en) * 2009-12-21 2011-07-14 Merck Sharp & Dohme Corp. Aminobenzoquinazolinone m1 receptor positive allosteric modulators
TWI402264B (zh) * 2010-05-12 2013-07-21 Merck Sharp & Dohme 芳基甲基苯并喹唑啉酮m1受體之正向異位性調節劑
US9586964B2 (en) 2011-10-28 2017-03-07 Vanderbilt University Substituted 2-(4-heterocyclylbenzyl)isoindolin-1-one analogs as positive allosteric modulators of the muscarinic acetylcholine receptor M1
WO2013071201A1 (en) 2011-11-11 2013-05-16 Vanderbilt University Substituted benzylspiroindolin-2-one analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m1
US8697888B2 (en) * 2012-01-06 2014-04-15 Vanderbilt University Substituted (1-(methylsulfonyl)azetidin-3-yl)(heterocycloalkyl)methanone analogs as antagonists of muscarinic acetylcholine M1 receptors
US9029563B2 (en) 2012-01-06 2015-05-12 Vanderbilt University Substituted 1-benzylindolin-2-one analogs as positive allosteric modulators of muscarinic acetylcholine M1 receptors
US9012445B2 (en) 2012-01-12 2015-04-21 Vanderbilt University Substituted 4-(1H-pyrazol-4-yl)benzyl analogues as positive allosteric modulators of mAChR M1 receptors
US9403802B2 (en) 2012-03-02 2016-08-02 Takeda Pharmaceutical Company Limited Heterocyclic compound and use therefor
WO2014077401A1 (ja) 2012-11-19 2014-05-22 武田薬品工業株式会社 含窒素複素環化合物
US20160368897A1 (en) 2013-06-28 2016-12-22 Emory University Pyrazoline Dihydroquinolones, Pharmaceutical Compositions, and Uses
US9708278B2 (en) 2013-11-27 2017-07-18 Vanderbilt University Substituted 4-benzyl-3,4-dihydro-2H-benzo[B][1,4]oxazine-2-carboxamide analogs as positive allosteric modulators of muscarinic acetycholine receptor M1
US11981652B2 (en) 2018-03-28 2024-05-14 Emory University GluN2C/D subunit selective antagonists of the N-methyl-D-aspartate receptor
CN118829630A (zh) * 2023-02-17 2024-10-22 凯思凯迪(上海)医药科技有限公司 一种多环类甲状腺激素β受体激动剂及其用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2241891A1 (en) 1996-02-21 1997-08-21 Darwin Discovery Limited Quinolones and their therapeutic use
AU2002352878B2 (en) * 2001-11-27 2007-11-22 Merck Sharp & Dohme Corp. 2-Aminoquinoline compounds
WO2007067489A1 (en) 2005-12-05 2007-06-14 Merck & Co., Inc. Quinolone m1 receptor positive allosteric modulators

Also Published As

Publication number Publication date
US8178667B2 (en) 2012-05-15
EP2037739A2 (de) 2009-03-25
JP2009542663A (ja) 2009-12-03
AU2007265412A1 (en) 2008-01-03
WO2008002621A3 (en) 2008-02-21
EP2037739A4 (de) 2010-08-11
US20100009962A1 (en) 2010-01-14
CA2655787A1 (en) 2008-01-03
WO2008002621A2 (en) 2008-01-03
EP2037739B1 (de) 2011-10-26

Similar Documents

Publication Publication Date Title
WO2008002621A3 (en) Benzyl-substituted quinolone m1 receptor positive allosteric modulators
ATE475650T1 (de) Positive allosterische chinolon-m1- rezeptormodulatoren
TN2011000209A1 (en) Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators
TN2012000231A1 (en) Quinoline amide m1 receptor positive allosteric modulators
EP2582676A4 (de) Positive allosterische tetrahydrochinolin-amid-m1-rezeptormodulatoren
MX2012002583A (es) Moduladores de piranil aril metil benzoquinazolinona alostericos positivos del receptor m1.
TW200728305A (en) Spiropiperidine beta-sectetase inhibitors for the treatment of alzheimer's disease
BR0316350A (pt) Diaminotriazóis úteis como inibidores de proteìna cinases
EA200901373A1 (ru) Аминогетероциклические соединения
EA200971107A1 (ru) Катехоламиновые производные, полезные для лечения болезни паркинсона
EA201171197A8 (ru) Замещенные производные азоантрацена, фармацевтические композиции и способы их применения
UA99309C2 (ru) Замещенные пиперидинодигидротиенопиримидины
EA201300471A1 (ru) Замещенные 6-аминоникотинамиды в качестве модуляторов kcnq2/3
ATE538651T1 (de) Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
EA200802020A1 (ru) Тетрагидропиримидоазепины и их применение в качестве модуляторов trpv 1
MY147677A (en) Piperazinyl derivatives useful in the treatment of gpr38 receptor mediated diseases
ATE552257T1 (de) Positive allosterische chinolizidinon-m1- rezeptormodulatoren
CY1115384T1 (el) Αντι-φλεγμονωδης συνθεση
EP1817312A4 (de) Makrozyklische aminiopyridyl-beta-sekretase-hemmer zur behandlung von morbus alzheimer
ATE538796T1 (de) Piperidin- und pyrrolidin-beta-secretase-hemmer zur behandlung von alzheimer-krankheit
WO2009117283A3 (en) Quinolizidinone m1 receptor positive allosteric modulators
CY1116158T1 (el) Υποκατεστημενα 2-οξο- και 2-θειοξο-διυδροκινολινο-3-καρβοξαμιδια σαν διαμορφωτες kcnq2/3
WO2009134668A3 (en) 4-oxo-1,4-dihydroquinoline m1 receptor positive allosteric modulators
ATE474574T1 (de) Imidazoazephinonverbindungen
EA200801302A1 (ru) Композиции и способы лечения нарушений цнс

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties